Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Title: Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Brief Patent Description - Full Patent Description - Patent Claims

The Patent Description & Claims data below is from USPTO Patent Application 20090162318, Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors.

We claim:

1. A composition comprising a compound of formula I, a pharmaceutically acceptable carrier, and at least one additional compound having therapeutic benefits for HCV where: R1 is CO2R5 or CONR6R7; R3 is hydrogen, halo, alkyl, alkenyl, hydroxy, benzyloxy, alkoxy, or haloalkoxy; R4 is cycloalkyl; R5 is hydrogen or alkyl; R6 is hydrogen, alkyl, alkylSO2, cycloalkylSO2, haloalkylSO2, (R9)2NSO2, or (R10)SO2; R7 is hydrogen or alkyl; R8 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, alkylcarbonyl, cycloalkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, alkylSO2, cycloalkylSO2, haloalkylSO2, aminocarbonyl, (alkylamino)carbonyl, (dialkylamino)carbonyl, benzyl, benzyloxycarbonyl, or pyridinyl; R9 is hydrogen, alkyl, or cycloalkyl; and R10 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperidinyl, or homomorpholinyl and is substituted with 0-3 alkyl substituents; or a pharmaceutically acceptable salt thereof; and where the additional compound having therapeutic benefits for HCV is selected from the group consisting of interferons, cyclosporins, interleukins, HCV metalloprotease inhibitors, HCV serine protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, HCV NS4B protein inhibitors, HCV entry inhibitors, HCV assembly inhibitors, HCV egress inhibitors, HCV NS5A protein inhibitors, HCV NS5B protein inhibitors, and HCV replicon inhibitors.

2. A method of treating hepatitis C infection comprising administering a therapeutically effective amount of a compound of formula I and at least one additional compound having therapeutic benefits for HCV to a patient where: R1 is CO2R5 or CONR6R7; R3 is hydrogen, halo, alkyl, alkenyl, hydroxy, benzyloxy, alkoxy, or haloalkoxy; R4 is cycloalkyl; R5 is hydrogen or alkyl; R6 is hydrogen, alkyl, alkylSO2, cycloalkylSO2, haloalkylSO2, (R9)2NSO2, or (R10)SO2; R7 is hydrogen or alkyl; R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, alkylcarbonyl, cycloalkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, alkylSO2, cycloalkylSO2, haloalkylSO2, aminocarbonyl, (alkylamino)carbonyl, (dialkylamino)carbonyl, benzyl, benzyloxycarbonyl, or pyridinyl; R9 is hydrogen, alkyl, or cycloalkyl; and R10 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperidinyl, or homomorpholinyl and is substituted with 0-3 alkyl substituents; or a pharmaceutically acceptable salt thereof, and where the additional compound having therapeutic benefits for HCV is selected from the group consisting of interferons, cyclosporins, interleukins, HCV metalloprotease inhibitors, HCV serine protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, HCV NS4B protein inhibitors, HCV entry inhibitors, HCV assembly inhibitors, HCV egress inhibitors, HCV NS5A protein inhibitors, HCV NS5B protein inhibitors, and HCV replicon inhibitors.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors patent application.

Patent Applications in related categories:

20090291061 - Stem cell therapy for blood vessel degeneration - The present disclosure provides means of treating degenerated blood vessels through administration of stem cells or activators of stem cells. In one particular embodiment vessel reactivity is increased through administration of stem cells or stem cell activating compounds. Other embodiments include “reconditioning” of vessels prone to aneurysms, repairing aneurysms of ...

20090291060 - Treatment of hiv - We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments. ...

###

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.
Start now! - Receive info on patent apps like Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors or other areas of interest.
###

Previous Patent Application:
Magnesium-containing polymers for the treatment of hyperphosphatemia
Next Patent Application:
Enterotoxin gene cluster (egc) superantigens to treat malignant disease
Industry Class:
Drug, bio-affecting and body treating compositions

###

Design/code © 2009 FreshContext LLC/Freshpatents.com. Website Terms and Conditions - Also read: About this Page
Patent data source: patents published by the United States Patent and Trademark Office (USPTO)
Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and often contain additional data/images (Freshpatents is currently text-only). FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents.

FreshPatents.com Support
Thank you for viewing the Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors patent info.
IP-related news and info

Results in 3.99609 seconds

Other interesting Feshpatents.com categories:
Daimler Chrysler , DirecTV , Exxonmobil Chemical Company , Goodyear , Intel , Kyocera Wireless , paws

* Protect your Inventions
* US Patent Office filing

Provisional Patent
Utility Patent

PATENT INFO